FDA Approves Bimzelx for Three New Indications
By Lori Solomon HealthDay Reporter
THURSDAY, Sept. 26, 2024 -- The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS).
Bimzelx selectively inhibits two key cytokines driving inflammatory processes -- interleukin 17A (IL-17A) and interleukin 17F (IL-17F). The FDA recommended dosage of Bimzelx across the three indications is 160 mg by subcutaneous injection every four weeks.
The expanded indication for PsA is supported by two phase 3 studies in which Bimzelx (compared with placebo) led to statistically significant improvements at week 16 in both joint and skin symptoms, across biologic-naive and tumor necrosis factor inhibitor-inadequate responder populations, with improvements sustained to week 52. For active nr-axSpA and AS, two phase 3 studies showed statistically significant improvements in signs and symptoms with Bimzelx (compared with placebo), which were also sustained to week 52.
"The approval of Bimzelx in the United States across three new indications highlights the clinical benefit of dual inhibition of both IL-17A and IL-17F for patients, and provides an opportunity for more people living with chronic inflammatory diseases to achieve meaningful outcomes," Emmanuel Caeymaex, the executive vice president and chief commercial officer at UCB, said in a statement.
These approvals for Bimzelx were granted to UCB.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Psoriasis, Psoriatic Arthritis Tied to Higher Risk of Polyneuropathy
MONDAY, July 29, 2024 -- Psoriasis and psoriatic arthritis may be associated with an increased risk of polyneuropathy, according to a study published online June 28 in Muscle...
Psoriasis, With or Without Psoriatic Arthritis, Associated With Fatigue
MONDAY, July 1, 2024 -- Psoriasis is associated with fatigue, especially among those with psoriatic arthritis (PsA), according to a study published in the July issue of the...
FDA Expands Pediatric Indication for Rinvoq
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has expanded indications for Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.